{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:22:35Z","timestamp":1772749355484,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.biopha.2009.01.008","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T21:51:38Z","timestamp":1234389098000},"page":"635-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats"],"prefix":"10.1016","volume":"63","author":[{"given":"Keizo","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Mizuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Uchisako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kobuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2009.01.008_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.01.008_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2105\/AJPH.91.7.1060","article-title":"HIV in the United States at the turn of the century: an epidemic in transition","volume":"91","author":"Karon","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.biopha.2009.01.008_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/00002030-199813000-00010","article-title":"Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection","volume":"12","author":"d'Arminio Monforte","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2009.01.008_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/JVI.75.2.589-594.2001","article-title":"Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and\/or saquinavir","volume":"75","author":"Cote","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.biopha.2009.01.008_bib5","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2009.01.008_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00002018-200023010-00004","article-title":"Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?","volume":"23","author":"Behrens","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.biopha.2009.01.008_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.01.008_bib8","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1097\/00002030-200012010-00021","article-title":"Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy","volume":"14","author":"Friedl","year":"2000","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2009.01.008_bib9","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1097\/00002030-200304001-00018","article-title":"Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease","volume":"17","author":"Behrens","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2009.01.008_bib10","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1086\/344179","article-title":"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death","volume":"35","author":"Hare","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biopha.2009.01.008_bib11","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1128\/AAC.45.12.3445-3450.2001","article-title":"Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin","volume":"45","author":"Hsyu","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2009.01.008_bib12","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1086\/386291","article-title":"Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens","volume":"189","author":"Colonno","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biopha.2009.01.008_bib13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00126334-200406010-00005","article-title":"Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir","volume":"36","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2009.01.008_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1590\/S1413-86702007000200025","article-title":"Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: reversion after switching (stavudine to tenofovir and lopinavir\/ritonavir to atazanavir\/ritonavir)","volume":"11","author":"Domingos","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.biopha.2009.01.008_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/EJE-06-0648","article-title":"Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects","volume":"156","author":"Guffanti","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.biopha.2009.01.008_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1592\/phco.28.3.323","article-title":"Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus","volume":"28","author":"Nguyen","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2009.01.008_bib17","first-page":"174","article-title":"Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia","volume":"39","author":"Mobius","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2009.01.008_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.2042-7158.1982.tb04194.x","article-title":"Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure","volume":"34","author":"Bower","year":"1982","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.biopha.2009.01.008_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cpt1979253316","article-title":"Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia","volume":"25","author":"Danon","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopha.2009.01.008_bib20","first-page":"61","article-title":"Factors influencing isradipine and amlodipine binding to human plasma lipoproteins","volume":"1","author":"Oravcova","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.biopha.2009.01.008_bib21","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/1520-6017(200008)89:8<1008::AID-JPS5>3.0.CO;2-B","article-title":"Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins","volume":"89","author":"Schuhmacher","year":"2000","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biopha.2009.01.008_bib22","doi-asserted-by":"crossref","first-page":"448P","DOI":"10.1111\/j.1365-2125.1978.tb00871.x","article-title":"Plasma protein binding interaction between valproic acid and palmitic acid in vitro [proceedings]","volume":"6","author":"Monks","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopha.2009.01.008_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0003-2697(81)90243-8","article-title":"Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum","volume":"111","author":"Terpstra","year":"1981","journal-title":"Anal Biochem"},{"key":"10.1016\/j.biopha.2009.01.008_bib24","first-page":"1349","article-title":"Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat","volume":"33","author":"Bollman","year":"1948","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.biopha.2009.01.008_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/bmc.134","article-title":"Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry","volume":"16","author":"Gao","year":"2002","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.biopha.2009.01.008_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3999\/jscpt.29.475","article-title":"Development and evaluation of noncompartmental pharmacokinetic analysis program WinHARMONY using Visual BASIC language having a function of automatic recognition vs time profile","volume":"29","author":"Yoshikawa","year":"1998","journal-title":"Rinsho Yakuri"},{"key":"10.1016\/j.biopha.2009.01.008_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/bdd.476","article-title":"The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat","volume":"27","author":"Brocks","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.biopha.2009.01.008_bib28","doi-asserted-by":"crossref","first-page":"E672","DOI":"10.1208\/aapsj080477","article-title":"Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function","volume":"8","author":"Aliabadi","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.biopha.2009.01.008_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.457","article-title":"Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models","volume":"26","author":"Shayeganpour","year":"2005","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.biopha.2009.01.008_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1018896912889","article-title":"Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat","volume":"16","author":"Eliot","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.biopha.2009.01.008_bib31","first-page":"192","article-title":"Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats","volume":"46","author":"Wout","year":"1992","journal-title":"J Parenter Sci Technol"},{"key":"10.1016\/j.biopha.2009.01.008_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jps.2600700208","article-title":"Ultrafiltration in serum protein binding determinations","volume":"70","author":"Whitlam","year":"1981","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biopha.2009.01.008_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/clinchem\/31.1.60","article-title":"Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid","volume":"31","author":"Barre","year":"1985","journal-title":"Clin Chem"},{"key":"10.1016\/j.biopha.2009.01.008_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2125.1998.00663.x","article-title":"Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin","volume":"45","author":"Simon","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopha.2009.01.008_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/FTD.0b013e3181817318","article-title":"Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction","volume":"30","author":"Fayet","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.biopha.2009.01.008_bib36","doi-asserted-by":"crossref","unstructured":"Sugioka N, Haraya K, Yuta M, Fukushima K, Takada K. Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats. Biol Pharm Bull 2008;32:269\u201375.","DOI":"10.1248\/bpb.32.269"},{"key":"10.1016\/j.biopha.2009.01.008_bib37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1128\/AAC.45.4.1184-1191.2001","article-title":"Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities","volume":"45","author":"Ramaswamy","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2009.01.008_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.38.2.223","article-title":"Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B","volume":"38","author":"Wasan","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.biopha.2009.01.008_bib39","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S0022-2275(20)37861-5","article-title":"Lipoprotein metabolism in the suckling rat: characterization of plasma and lymphatic lipoproteins","volume":"24","author":"Fernando-Warnakulasuriya","year":"1983","journal-title":"J Lipid Res"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:43:30Z","timestamp":1760093010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332209000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0753332209000225"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2009.01.008","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2009.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}